ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2021
Short-term choroidal vascular changes after aflibercept therapy for neovascular age-related macular degeneration.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05662410 (Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy), which is not on this map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Choroidal Morphology Changes After Aflibercept Therapy in Pachychoroid Neovasculopathy
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Short-term outcomes and choroidal morphological changes following aflibercept therapy in pachychoroid neovasculopathy.Scientific reports · 2026Trial
- Wide-field choroidal thickness changes after loading-phase anti-VEGF therapy in treatment-naïve neovascular AMD.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Five-year real-world outcomes and patterns of MNV-related atrophy after anti-VEGF therapy in eyes with pathologic myopia.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- Analysis of the therapeutic effects of anti-vascular endothelial growth factor treatment based on indocyanine green angiographic staining patterns in patients with central serous chorioretinopathy.Indian journal of ophthalmology · 2026Article
- Real-World Outcomes and Choroidal Vascular Structural Changes After Switching to Faricimab in Neovascular Age-Related Macular Degeneration.Journal of clinical medicine · 2026Article
- Reduced ocular perfusion after intravitreal Aflibercept and faricimab: an exploratory study for Tie2 receptor distribution in ophthalmic capillaries.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2026Article
- A Pilot Study on Structural Changes of Choroidal Vasculature Following Intravitreal Anti-VEGF Injection in Neovascular Age-Related Macular Degeneration: Faricimab vs Ranibizumab.Journal of clinical medicine · 2025Article
- Comparable choroidal thickness between treated eyes and untreated fellow-eyes in patients with unilateral neovascular AMD: a paired-eyes comparative study.Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2025Article
- Updates on novel and traditional OCT and OCTA biomarkers in nAMD.Eye (London, England) · 2025Review
- Resolution of subretinal fluid in intractable central serous chorioretinopathy with high-dose intravitreal aflibercept.American journal of ophthalmology case reports · 2025Article
- A pilot study : retinal sensitivity change in neovascular age-related macular degeneration patients with better baseline visual acuity.Scientific reports · 2024Article
- Evaluation of Choroidal Structure in Type 1 Macular Neovascularization Using Different Optical Coherence Tomography Analyses: Scale Bar and Binarization.Journal of clinical medicine · 2024Article
- Treatment of neovascular age-related macular degeneration: one year real-life results with intravitreal Brolucizumab.Frontiers in medicine · 2024Article
- Choroidal Changes After Anti-VEGF Therapy in AMD Eyes With Different Types of Macular Neovascularization Using Swept-Source OCT Angiography.Investigative ophthalmology & visual science · 2023Article
- Postoperative Choroidal Vascular Biomarkers in Eyes with Rhegmatogenous Retinal Detachment-Related Giant Retinal Tears.International journal of retina and vitreous · 2023Article
- Influence of protocol scan on choroidal vascularity measurements: a spectralis optical coherence tomography study.Eye (London, England) · 2023Article
- Outer nuclear layer recovery as a predictor of visual prognosis in type 1 choroidal neovascularization of neovascular age-related macular degeneration.Scientific reports · 2023Article
- Choroidal and Retinal Imaging Biomarkers in Different Types of Macular Neovascularization.Journal of clinical medicine · 2023Article
- Decrease in Ocular Blood Flow Thirty Minutes After Intravitreal Injections of Brolucizumab and Aflibercept for Neovascular Age-Related Macular Degeneration.Clinical ophthalmology (Auckland, N.Z.) · 2023Article
- Comparison of the regressive effects of aflibercept and brolucizumab on pigment epithelial detachment.BMC ophthalmology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe purpose of this study was to evaluate choroidal vascular changes in patients with neovascular age-related macular degeneration (nAMD) treated with aflibercept injection over a 3-month period.
methodsEnhanced depth imaging optical coherence tomography scans of 60 eyes with treatment-naïve nAMD and 60 unaffected fellow eyes were retrospectively analyzed. Data was collected at baseline and after 3 monthly intravitreal injections of aflibercept. The ImageJ software was used to binarize OCT scans and measure total choroid area (TCA), luminal area (LA), and stromal area (SA). Choroidal vascularity index (CVI) was defined as the ratio of LA to TCA.
resultsAfter treatment, subfoveal choroidal thickness (CT) in nAMD eyes significantly decreased from 210. 6 ± 61.6 to 194.6 ± 58.7 μm (P < 0.001), TCA from 1.620 ± 0.502 to 1.500 ± 0.451 mm
conclusionChoroidal thickness and vascularity significantly decreased after treatment with aflibercept in nAMD eyes. Besides the pharmacologic effect on the neovascular lesion, aflibercept may induce vascular changes also on the underlying choroid.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.